We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Since 2008, there has been no “consistent increase” in ...

Please provide your email address to receive an email when new articles are posted on . PHILADELPHIA — Patients with juvenile idiopathic arthritis started on conventional synthetic and biologic ...

CORRECTED April 15, 2024 // An earlier version of this article stated incorrect percentages of patients who never received any biologics during the study's 3-year period but improved rapidly or ...

Weaker immune response against COVID-19 may be attributed to the more targeted immunosuppressive mechanism of biologic DMARDs. Rheumatoid arthritis (RA) patients receiving biologic disease-modifying ...

ROME — Daily baricitinib, an oral Janus kinase (JAK)1/2 inhibitor, produces rapid clinical improvement in the signs and symptoms of rheumatoid arthritis in patients with active disease who have failed ...

For patients with polyarticular juvenile idiopathic arthritis (JIA), a strategy of using early combination therapy led to better outcomes than a traditional step-up approach or initial biologic ...

In recent years, the treatment of rheumatic inflammatory diseases has been revolutionized. With the advent of biologic and targeted synthetic disease-modifying antirheumatic drugs (DMARDs), minimal ...